Core Viewpoint - The performance of certain equity funds has been outstanding in the context of a rising market, particularly in the pharmaceutical sector, with a significant number of funds achieving over 100% returns year-to-date and over the past year [1][3][4]. Fund Performance - As of July 29, 23 funds have achieved a year-to-date return of over 100%, with 70% of these being related to the pharmaceutical sector [3][4]. - The leading fund, Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund (QDII) C, has a year-to-date return of 139.12%, followed closely by other funds with returns of 138.9% and 129.35% [3][4]. - Over the past year, a total of 134 funds have doubled their returns, with the top-performing fund, CITIC Securities North Exchange Two-Year Open Mixed A, achieving a remarkable 207.48% return [4][5]. Sector Focus - The majority of the "doubling funds" are focused on innovative drugs and related products, with over 60 funds containing terms like "pharmaceutical," "innovative drugs," and "biotechnology" in their names [4][5]. - The top-performing funds in the innovative drug sector include those managed by well-known fund managers, with returns nearing 100% for some [5][6]. Market Outlook - Industry experts remain optimistic about the innovative drug sector, citing strong performance in the first half of the year and potential for continued growth in the second half [6][7]. - There is an expectation of structural opportunities in the consumer healthcare sector, particularly in areas like medical aesthetics and home medical devices, driven by increasing health awareness among consumers [7][8]. - The outlook for innovative drugs is bolstered by government support measures and anticipated developments in overseas licensing and domestic sales [8].

Group 1 - The overall market has seen significant growth in 2023, with 23 funds achieving over 100% returns year-to-date, predominantly in the pharmaceutical sector [1][3] - Among these, 17 funds are focused on innovative drugs, making up over 70% of the "doubling funds," with the top performers including 汇添富香港优势精选混合 (QDII) C at 139.12% [4][6] - Over the past year, a total of 134 funds have doubled their returns, with the top fund, 中信建投北交所两年定开混合 A, achieving a remarkable 207.48% return [4][5] Group 2 - The pharmaceutical sector remains a focal point for investment, with analysts optimistic about the innovative drug market and its potential for continued growth [6][7] - Key stocks in high-performing funds include 三生制药 and 科伦博泰生物-B, which have seen substantial price increases of 428.9% and 138% respectively [6][7] - The outlook for the third quarter suggests ongoing opportunities in the innovative drug space, driven by global collaborations and significant clinical data releases [6][7]

Core Viewpoint - The State Council's press conference highlighted the deepening of medical insurance reform during the 14th Five-Year Plan, emphasizing the principle of "anti-involution" in the 11th batch of centralized procurement, which aims to stabilize drug prices and improve profitability in the pharmaceutical industry [1][2]. Group 1: Centralized Procurement and Policy Changes - The National Medical Insurance Administration (NMI) has initiated the 11th batch of centralized procurement, focusing on principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and anti-involution" [1]. - The NMI has optimized procurement rules, moving away from a simple lowest price reference, which previously led to low pricing and affected profitability and quality [2][3]. - The new rules require the lowest bidding companies to justify their pricing and ensure it does not fall below cost, indicating a potential improvement in drug pricing dynamics [1][2]. Group 2: Pharmaceutical Industry Outlook - The pharmaceutical sector is expected to gradually recover from the impacts of centralized procurement, with policy shifts and improved profitability on the horizon [3]. - The industry has seen significant R&D investments, and many companies are entering a phase of product realization, enhancing their competitive edge globally [3]. Group 3: Investment Opportunities - Three main investment lines are suggested: 1. Areas with stable growth, particularly in medical devices and pharmaceuticals, with specific companies highlighted for potential investment [4]. 2. The CXO and medical equipment sectors are anticipated to benefit from favorable domestic financing and fiscal policies, with recommended companies listed [5]. 3. Innovative fields related to national medical insurance negotiations, focusing on companies with international expansion capabilities [5]. - Additional sectors of interest include traditional Chinese medicine, raw materials, medical services, vaccines, and retail pharmacies, with specific companies identified for potential investment [6][7].

Group 1 - The global market for Multiple Sclerosis (MS) products is approximately $20 billion, with a significant focus on Relapsing Multiple Sclerosis (RMS) treatments [1][2] - The existing approved products primarily target RMS, while there is a notable unmet clinical need in the Progressive Multiple Sclerosis (PMS) area, with only one product, Ocrelizumab, approved for Primary Progressive Multiple Sclerosis (PPMS) [2][3] - The patient base for MS is substantial, with projections indicating that the number of MS patients globally will reach 3.71 million by 2030 [1] Group 2 - BTK inhibitors are expected to address the treatment gap in PMS, with their ability to penetrate the blood-brain barrier and modulate key immune cells [3] - Sanofi's Tolebrutinib and Roche's Fenebrutinib are anticipated to release Phase III clinical trial data in the second half of 2025, which could enhance the value of BTK inhibitors in PMS [3][4] - Tolebrutinib has received priority review from the FDA for the treatment of non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS), with a PDUFA date set for September 28, 2025 [4]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong innovative drug sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) reaching a historical high, increasing by 4.18% [1] - The Hong Kong Stock Connect Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has seen a year-to-date increase of 107.56%, outperforming other innovative drug indices [2][3] - Major stocks in the innovative drug sector, such as Innovent Biologics, CSPC Pharmaceutical Group, and WuXi AppTec, have shown significant gains, with Innovent Biologics rising over 3% and others increasing by more than 1% [1][2] Group 2 - Analysts indicate that the innovative drug sector remains a clear trend within the pharmaceutical industry, with substantial growth potential and attractive valuations, suggesting increased foreign investment in Hong Kong innovative drugs [4] - The performance of the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has varied over the years, with historical declines in 2021, 2022, 2023, and 2024, but the current year shows a strong recovery [3]

Investment Rating - The investment rating for the biotechnology industry is "Positive" (maintained) [1] Core Insights - The global stock of multiple sclerosis (MS) patients is significant, with the market size exceeding $20 billion, primarily focused on relapsing forms of MS (RMS) [6][9] - BTK inhibitors are expected to fill the treatment gap in primary progressive MS (PPMS) and non-relapsing secondary progressive MS (nrSPMS) [7][9] - The anticipated release of clinical data for BTK inhibitors in the second half of 2025 is expected to enhance the attractiveness of the sector [9] Summary by Sections 1. Multiple Sclerosis Overview - MS is an immune-mediated inflammatory demyelinating disease of the central nervous system, characterized by "spatial" and "temporal" multiplicity [5][27] - The global and Chinese stock of MS patients is projected to reach 3.71 million and 60,000 respectively by 2030, with a CAGR of approximately 2.7% and 2.1% from 2025 to 2030 [19][22] 2. Market Size and Product Landscape - The global MS market is approximately $20 billion, with a focus on RMS treatments [6][40] - Existing products include monoclonal antibodies and oral therapies, with CD20 monoclonal antibodies expected to account for over 60% of sales by 2024 [6][46] 3. BTK Inhibitors and Clinical Development - BTK inhibitors are positioned to address unmet needs in the treatment of PPMS and nrSPMS, with several candidates in late-stage clinical trials [7][51] - Tolebrutinib and Fenebrutinib are expected to release pivotal clinical data in the second half of 2025, which could significantly impact their market potential [8][51] 4. Investment Recommendations - The ongoing clinical developments and the large patient base present significant investment opportunities in companies like 诺诚健华, 翰森制药, 云顶新耀, 恒瑞医药, and 百济神州-U [9]

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the benchmark index over the next 6-12 months [10]. Core Insights - The National Healthcare Security Administration (NHSA) has clarified its stance on centralized procurement, emphasizing a "anti-involution" principle, which is expected to stabilize drug prices and improve profitability in the pharmaceutical sector [1][2]. - The NHSA's new procurement rules aim to enhance the quality of drugs and ensure that companies provide reasonable pricing justifications, which is anticipated to lead to a gradual recovery in the profitability of pharmaceutical companies [1][2]. - The pharmaceutical sector is expected to gradually emerge from the impacts of centralized procurement, with a focus on valuation re-evaluation opportunities as policies and corporate earnings improve [1][2]. Summary by Sections Section: Centralized Procurement - The NHSA has initiated the 11th batch of centralized procurement, adhering to principles of stability, quality assurance, and anti-involution, with specific measures to optimize procurement rules [1][2]. - Previous procurement methods primarily focused on price reduction, adversely affecting company profitability and drug quality, but the new measures are expected to foster a healthier competitive environment [1][2]. Section: Investment Opportunities - The report suggests focusing on three main investment lines: 1. Areas with stable growth, particularly in medical devices and pharmaceuticals, where the impact of centralized procurement is gradually dissipating [1][3]. 2. The CXO sector and medical equipment, which are expected to see a reversal due to favorable domestic financing and fiscal policies [1][3]. 3. Innovative fields that are entering a phase of realization or expansion, particularly companies with international capabilities [1][3]. Section: Recommended Stocks - Suggested stocks in the medical device sector include: - Medical consumables: Bairen Medical, Sanyou Medical, Kangwei Century, Dabo Medical, Aikang Medical, Weigao Orthopedics - Ophthalmology: Aibo Medical - Cardiovascular: Huitai Medical, Xinmai Medical, Lepu Medical - In the pharmaceutical sector, recommended stocks include: - Heng Rui Medicine, Xin Li Tai, Jingxin Pharmaceutical, Xianju Pharmaceutical, Kangchen Pharmaceutical [1][3].

相关事件 港股收评：恒生指数涨0.62%！光伏、钢铁成亮点，军工、芯片股表现疲软 港股收评：恒生指数跌 0.56%！内房股、汽车股低迷，黄金股逆势爆发 港股收评：三大指数涨跌不一，恒生科技指数涨 0.56%，医药、军工、汽车大涨 港股收评：恒指再度失守24000，恒生科技指数跌0.33%，医药、芯片、 券商大涨居前 港股三大指数午后持续回升跌幅明显缩窄，恒生指数、国企指数分别下跌0.15%及0.34%，二者盘中均 跌至1.2%，恒生科技指数盘中更是大跌2%，最终收跌0.35%。值得注意的是，在指数调整之际，南下资 金大幅净买入港股超100亿港元。 另一方面，3600元生育补贴落地，三胎概念股呈现高开低走行情，内银股全天表现低迷，工商银行、建 设银行、农业银行均走低，餐饮股、机器人概念股普遍下跌。(格隆汇) 盘面上，午后大型科技股跌幅收窄，尤其是阿里巴巴小幅转涨，腾讯、京东、美团、快手跌幅在1%以 内，小米走势较弱仍下跌2.6%，百度跌近2%；生物医药股全天表现强势行情，创新药方向涨幅抢眼， 其中，药明康德大涨超11%，石药集团、绿叶制药涨超8%，信达生物、三生制药、诺诚健华、百济神 州纷纷上涨；"反内卷"部分 ...

Market Overview - The Hang Seng Index closed at 25,524.45, down by 0.15%, while the Hang Seng China Enterprises Index fell by 0.34% to 9,145.92. The Hang Seng Tech Index decreased by 0.35% to 5,644.38, with intraday declines reaching 1.2% for the first two indices and a significant drop of 2% for the tech index [1] - Despite the index adjustments, southbound capital saw a substantial net purchase of Hong Kong stocks exceeding 10 billion HKD [1] Stock Performance - Notable gainers in the biopharmaceutical sector included WuXi AppTec (up 11.25%), with other companies like CSPC Pharmaceutical and Green Leaf Pharmaceutical also showing strong performance, rising over 8% [3] - The top-performing stocks included WuXi Biologics-B (up 33.33%), Chuangsheng Group-B (up 17.06%), and Dongyao Pharmaceutical-B (up 15.06%) [2] Sector Trends - Large tech stocks showed a narrowing of losses in the afternoon, with Alibaba slightly turning positive, while Tencent, JD.com, Meituan, and Kuaishou experienced declines within 1%. Xiaomi fell by 2.6%, and Baidu dropped nearly 2% [3] - The "anti-involution" sectors, including steel and photovoltaic stocks, saw a rebound, while sectors like banking, catering, and robotics generally declined [3]

除葛兰外，其他基金经理也对创新药青睐有加。兴证全球基金谢治宇管理的兴全合宜，二季度有 信达生物 、 诺 诚健华 、诺诚健华- U 3只创新药个股进入前十大持仓。谢治宇认为，创新药、智驾汽车、新消费等更具现实业绩 支撑的产业性机会，更适合以机构为主的价值投资者参与。 一些原本不关注医药领域的基金经理也纷纷入场。睿远基金傅鹏博在二季度增加了医药板块配置，涉及创新药等 子行业；永赢基金高楠管理的永赢睿信，在将 康方生物 、百济神州- U买进重仓股后，还在继续加码创新药。 基金二季报显示，创新药板块正成为投资老将们的"心头好"。在政策支持、技术进步、全球合作深化等多重因素 推动下，创新药行业前景广阔，未来有望为投资者带来更多惊喜，市场也将持续关注基金经理们在创新药领域的 后续布局。 以中欧基金葛兰为例，其管理的中欧医疗健康混合A二季度前十大重仓股变动显著， 迈瑞医疗 、 爱尔眼科 等退 出， 百利天恒 、 信立泰 、 百济神州 、 新诺威 4只创新药个股新进。 展望三季度，在创新药领域，中欧基金葛兰在二季报中表示，看好全球合作深化与重要临床数据披露预期。当 前，国内企业在ADC、双抗、多肽等领域的竞争力逐步获得全球认 ...